ABBV
AbbVie Inc.
ABBV has the edge over UNH overall, supported by stronger fundamentals.
UNH
UnitedHealth Group Incorporated
UNH has slightly lower modeled downside risk, despite its lower overall score.
ABBV Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Stable |
ABBV's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ABBV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $294 | — |
| Cheap | 21x | $121 | -59% |
| Fair | 38x | $220 | -25% |
| Current | 51x | $294 | — |
| Expensive | 81x | $473 | +61% |
Historical ranges are pointers, not guarantees.
ABBV's PE is 51x, but its earnings don't support one, so it isn't a reliable read right now.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH has the edge over ABBV in the historical PE scenario, which offers more potential upside but is not a forecast.
ABBV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
ABBV has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ABBV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.81 | +172% |
| Q3 2026 | $5.81 | +340% |
| Q2 2026 | $3.54 | +69% |
| Q1 2026 | $2.03 | -14% |
| Q4 2025 | $2.36 | -1.7% |
| Q3 2025 | $1.32 | -54% |
| Q2 2025 | $2.10 | -30% |
| Q1 2025 | $2.35 | -30% |
| Q4 2024 | $2.40 | -12% |
ABBV earned $5.81 per share over the past year, about four times what it earned the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over ABBV on earnings, with more consistent year-over-year improvement.
ABBV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $17.4B | +10% |
| Q2 2026 | $17B | +10% |
| Q1 2026 | $15B | +12% |
| Q4 2025 | $16.6B | +10% |
| Q3 2025 | $15.8B | +9.1% |
| Q2 2025 | $15.4B | +6.6% |
| Q1 2025 | $13.3B | +8.4% |
| Q4 2024 | $15.1B | +5.6% |
ABBV has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 36% | +24 points |
| Q2 2026 | 38% | +6.1 points |
| Q1 2026 | 27% | -1.4 points |
| Q4 2025 | 27% | +37 points |
| Q3 2025 | 12% | -14 points |
| Q2 2025 | 32% | +4.1 points |
| Q1 2025 | 28% | +5.3 points |
| Q4 2024 | -9.9% | -32 points |
ABBV has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
ABBV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $7.3B | +10% |
| Q2 2026 | $3.1B | -36% |
| Q1 2026 | $3.6B | +155% |
| Q4 2025 | $4.9B | -28% |
| Q3 2025 | $6.6B | +28% |
| Q2 2025 | $4.9B | +141% |
| Q1 2025 | $1.4B | -64% |
| Q4 2024 | $6.8B | +49% |
ABBV's free cash flow has been positive every quarter for seven years: $18.9B over the past year, down 4.1% from the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
ABBV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +1M shares |
| 1 year | 0% | -- |
| 3 years | +0.1% | +1M shares |
| 5 years | -0.3% | -5M shares |
| Available history | +19% | +288M shares |
ABBV has 1.8B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5M |
| Q2 2026 | $9M |
| Q1 2026 | $1.5B |
| Q4 2025 | $3M |
| Q3 2025 | $4M |
| Q2 2025 | $12M |
| Q1 2025 | $961M |
| Q4 2024 | $358M |
ABBV spent $1.5B buying back its own shares over the past year, up 13% from the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ABBV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ABBV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.4x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 2.7x | Moderate |
| Q3 2025 | 3.6x | Elevated |
| Q2 2025 | 3.3x | Elevated |
| Q1 2025 | 3.5x | Elevated |
| Q4 2024 | 3.5x | Elevated |
ABBV's net debt is about 2.4 years of its operating earnings (EBITDA), down from 3.6 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH has the edge over ABBV on leverage, with a lower net debt burden relative to earnings.
ABBV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.4 | Overbought |
| Stochastic | 86.7 | Overbought |
ABBV's weekly RSI is 71 (overbought) and its Stochastic is 87 (overbought).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ABBV PE vs Healthcare Sector
| Metric | ABBV | Sector median | Relative |
|---|---|---|---|
| PE | 51x | 26x | 96% above |
| PE % | 64 | 29 | 35 pts above |
ABBV is trading at 51x earnings, a 96% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over ABBV on valuation relative to its sector.
ABBV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $281.9 | 4.4% above |
| 20 week MA | $266.1 | 11% above |
| 50 week MA | $238.2 | 24% above |
| 100 week MA | $219.0 | 34% above |
| 200 week MA | $190.8 | 54% above |
ABBV has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
ABBV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $89.2 | $103.3 | +16% |
| 2021 | $103.3 | $133.1 | +29% |
| 2022 | $133.1 | $163.1 | +23% |
| 2023 | $163.1 | $155.0 | -5% |
| 2024 | $155.0 | $178.0 | +15% |
| 2025 | $178.0 | $230.0 | +29% |
| 2026 YTD | $230.0 | $294.5 | +28% |
ABBV has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.